All subcategories » published, non RCT
Non-invasive evaluation of steatosis and fibrosis in the liver in adults patients living with cystic fibrosis.
primary studies published, non RCT
Details- 2025
- Piñar-Gutiérrez A
Long-term impact of Elexacaftor/Tezacaftor/ivacaftor on pulmonary, nutritional and metabolic outcomes in homozygous F508del cystic fibrosis patients: A real-world cohort study.
primary studies published, non RCT
Details- 2026
- Perrotta N
Impact of elexacaftor/tezacaftor/ivacaftor on gastrointestinal outcomes, inflammation, exocrine pancreatic function and fat malabsorption: Report of PROMISE pediatric substudy.
primary studies published, non RCT
Details- 2026
- Green N
Advancing Cystic Fibrosis-Related Diabetes Care With Automated Insulin Delivery Systems.
primary studies published, non RCT
Details- 2026
- Grancini V
Persistence of lung hyperinflation and small airway dysfunction in school-aged children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: results from the real-world MODUL-CF study.
primary studies published, non RCT
Details- 2026
- Colin L
Real-World Impact of Elexacaftor/Tezacaftor/Ivacaftor on Health-Related Quality of Life in Adults with Cystic Fibrosis: A 12-Month Multicenter Cohort Study.
primary studies published, non RCT
Details- 2026
- Kharraz R
Effect of elexacaftor-tezacaftor-ivacaftor on bronchial dilatations in adolescents with cystic fibrosis: a multicentre prospective observational study.
primary studies published, non RCT
Details- 2026
- Sermet-Gaudelus I
Evaluating Long-Term Effectiveness of Cystic Fibrosis Modulator Therapies After Rapid Adoption: A Dual-Approach Study.
primary studies published, non RCT
Details- 2025
- Afonso PM
20 years of the Montreal Cystic Fibrosis Related Diabetes Screening Cohort: key insights.
primary studies published, non RCT
Details- 2025
- Alexandre-Heymann L
Respiratory Outcomes and Aspergillus Serology Following Elexacaftor/Tezacaftor/Ivacaftor Therapy in People with Cystic Fibrosis and a History of Aspergillus fumigatus Infection.
primary studies published, non RCT
Details- 2025
- Lanfranchi C